Pharmacokinetic-pharmacodynamic comparison of ceftriaxone regimens in acute cholangitis.


Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 30 01 2019
revised: 27 03 2019
accepted: 08 04 2019
pubmed: 28 5 2019
medline: 28 1 2020
entrez: 28 5 2019
Statut: ppublish

Résumé

The most important factors determining the prognosis of patients with acute cholangitis (AC) are prompt biliary drainage and appropriate choice of antibiotics. This study was performed to evaluate whether dividing the number of doses based on the PK-PD theory contributes to better clinical outcome in the management of acute cholangitis. We measured ceftriaxone levels in blood and bile in 21 cases diagnosed with moderate-to-severe AC. Eleven cases were administered 2 g of ceftriaxone once-daily (group A) and 10 cases were given 1 g of ceftriaxone twice-daily (group B). The theoretical effect of ceftriaxone was evaluated by pharmacokinetic-pharmacodynamic (PK-PD) parameters. Clinical efficacy was evaluated by body temperature, white blood cell count and serum levels of C-reactive protein. Minimum level of ceftriaxone in serum (in mg/L) in groups A and B at 24 h after the first dose was 9.1 and 9.2, whereas that in bile was 2.9 and 2.5, respectively. The minimum inhibitory concentration (MIC) of ceftriaxone for all isolated bacteria was below the minimum serum and biliary concentration of ceftriaxone 24 h after the first administration (except for Enterococcus species). The MIC for isolated bacterial strains was <16 mg/L, which is the PK-PD breakpoint for ceftriaxone at 2 g/day. Both regimens showed clinical efficacy and did not contradict the effect predicted based on PK-PD.

Identifiants

pubmed: 31130393
pii: S1341-321X(19)30098-4
doi: 10.1016/j.jiac.2019.04.006
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ceftriaxone 75J73V1629
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

780-785

Informations de copyright

Copyright © 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Masao Toki (M)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan. Electronic address: ttt3nai@ks.kyorin-u.ac.jp.

Yasuharu Yamaguchi (Y)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Tomoyuki Goto (T)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Tsubasa Yoshida (T)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Hirotaka Ota (H)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Kazushige Ochiai (K)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Koichi Gondo (K)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Shunsuke Watanabe (S)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Isamu Kurata (I)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Tadakazu Hisamatsu (T)

Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH